RLYB trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RLYB achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Rallybio Corporation (RLYB) has a Wall Street consensus price target of N/A, based on estimates from 8 covering analysts. The company has a market capitalization of $91M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, RLYB trades at a trailing P/E of -10.7x. Analysts expect EPS to grow -168.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 PRAXPraxis Precision Medicines, Inc. | $8.2B | $295.51 | $603.83 | +104.3% | Buy | — | 18 |
 KYMRKymera Therapeutics, Inc. | $8.8B | $107.39 | $138.07 | +28.6% | Buy | — | 27 |
 ARQTArcutis Biotherapeutics, Inc. | $3.1B | $25.16 | $38.00 | +51.0% | Buy | 50.6x | 12 |
 TPSTTempest Therapeutics, Inc. | $12M | $0.81 | — | — | — | — | — |
 RVMDRevolution Medicines, Inc. | $43.9B | $206.64 | $252.35 | +22.1% | Buy | — | 24 |
 ALNYAlnylam Pharmaceuticals, Inc. | $29.3B | $219.72 | $347.33 | +58.1% | Buy | 33.0x | 52 |
 RAREUltragenyx Pharmaceutical Inc. | $1.5B | $15.22 | $26.25 | +72.5% | Buy | — | 33 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.86 | +2.6% | Buy | 40.6x | 24 |
 KRYSKrystal Biotech, Inc. | $9.5B | $322.28 | $395.20 | +22.6% | Buy | 42.4x | 17 |
Quick answers to the most common questions about buying RLYB stock.
The consensus price target for RLYB is $N/A, close to the current price of $17.08 (N/A% implied move). Based on 8 analyst estimates, the stock appears fairly valued near current levels.
RLYB has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
RLYB's current price is $17.08 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for RLYB, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
RLYB is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RLYB stock forecast based on 8 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
RLYB appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RLYB analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.